The Experts below are selected from a list of 1380 Experts worldwide ranked by ideXlab platform

Toshifumi Yamaguchi - One of the best experts on this subject based on the ideXlab platform.

  • efficacy of postoperative chemotherapy after resection that leaves no macroscopically visible disease of gastric cancer with positive peritoneal lavage cytology cy1 or localized Peritoneum Metastasis p1a a multicenter retrospective study
    Annals of Surgical Oncology, 2020
    Co-Authors: Toshifumi Yamaguchi, Rie Makuuchi, Atsuo Takashima, Kengo Nagashima, Tatsuya Yamada, Takahiro Kinoshita, Masaki Aizawa, Manabu Ohashi, Keitaro Tashiro, Hiroaki Hata
    Abstract:

    Gastric cancer (GC) patients with positive peritoneal lavage cytology (CY1) and/or localized Peritoneum Metastasis (P1a) are defined as stage IV in the 15th edition of the Japanese Classification of Gastric Cancer. In Japan, the most common treatment for patients with CY1 and/or P1a is gastrectomy followed by postoperative chemotherapy. Subjects in this multi-institutional retrospective study were GC patients with CY1 and/or P1a who received surgical resection that leaves no macroscopically visible disease. Patients were selected from 34 institutions in Japan between 2007 and 2012. Selection criteria included adenocarcinoma, no distant Metastasis except CY1 and P1a, and no prior treatment for GC before surgery. Among 824 patients registered, 506 were identified as eligible, with a background of P0CY1, P1aCY0, or P1aCY1 (72.5%, 16.0%, and 11.5% of subjects, respectively). Sixty-two patients had not received postoperative chemotherapy (no-Cx), whereas 444 patients had received postoperative chemotherapy: S-1 monotherapy (S-1; n = 267, 52.7%), cisplatin plus S-1 (CS; n = 114, 22.5%), and others (n = 63, 12.6%). Overall survival (OS) was 29.5, 24.7, 25.4 and 9.9 months in the S-1, CS, ‘others’, and no-Cx groups, respectively [CS vs. S-1: hazard ratio (HR) 1.15, 95% confidence interval (CI) 0.89–1.50; p = 0.275]. In multivariate analysis, OS was similar between the S-1 and CS groups (CS vs. S-1: HR 1.19, 95% CI 0.92–1.55; p = 0.18). Postoperative chemotherapy after gastrectomy that leaves no macroscopically visible disease may have some survival benefits for GC patients with CY1 and/or P1a. In contrast, S-1 plus cisplatin seems to have no additional benefit over S-1 treatment alone.

  • the impact of pre operative chemotherapy in patients with peritoneal lavage cytology positive or localized Peritoneum Metastasis for gastric cancer a multicenter retrospective study
    Journal of Clinical Oncology, 2018
    Co-Authors: Rie Makuuchi, Toshifumi Yamaguchi, Atsuo Takashima, Kengo Nagashima, Tatsuya Yamada, Takahiro Kinoshita, Hiroaki Hata, Yasuyuki Kawachi, Ryohei Kawabata, Toshikatsu Tsuji
    Abstract:

    95Background: Peritoneal lavage cytology of positive and localized Peritoneum Metastasis of gastric cancer (GC) are defined as CY1 and P1 in the 14th edition of the Japanese Classification of GC. P...

  • comparison of s 1 and s 1 plus cisplatin as post operative chemotherapy for gastric carcinoma with peritoneal lavage cytology positive or localized Peritoneum Metastasis a multicenter retrospective study
    Journal of Clinical Oncology, 2018
    Co-Authors: Masaki Aizawa, Toshifumi Yamaguchi, Atsuo Takashima, Kengo Nagashima, Akira Ema, Yasuhiro Yuasa, Shusuke Haruta, Hiroki Taniguchi, Daisuke Kobayashi, Kazuhiro Nishikawa
    Abstract:

    109Background: Peritoneal lavage cytology of class V and localized Peritoneum Metastasis of gastric cancer (GC) are defined as CY1 and P1 in the 14th edition of the Japanese Classification of GC. Because patients (pts) with CY1 and/or P1 have poor prognosis after resecting all macroscopically visible disease by standard surgical resection, post-operative chemotherapy (post-Cx) is commonly performed in the clinical practice in Japan. However, no standard chemotherapy has not been established. The aim of this study was to investigate the efficacy of post-Cx in patients with CY1 and/or P1. Methods: We retrospectively reviewed the GC pts who were diagnosed to have CY1 and/or P1 at 34 institutions participating in the Stomach Cancer Group of Japan Clinical Oncology Group between 2007 and 2012. Inclusion criteria were: PS 0-2, histology of adenocarcinoma, no distant Metastasis other than CY1 or P1, no prior treatment for GC. The subject of this study was the patients who received surgery followed by post-Cx. Re...

Atsuo Takashima - One of the best experts on this subject based on the ideXlab platform.

  • efficacy of postoperative chemotherapy after resection that leaves no macroscopically visible disease of gastric cancer with positive peritoneal lavage cytology cy1 or localized Peritoneum Metastasis p1a a multicenter retrospective study
    Annals of Surgical Oncology, 2020
    Co-Authors: Toshifumi Yamaguchi, Rie Makuuchi, Atsuo Takashima, Kengo Nagashima, Tatsuya Yamada, Takahiro Kinoshita, Masaki Aizawa, Manabu Ohashi, Keitaro Tashiro, Hiroaki Hata
    Abstract:

    Gastric cancer (GC) patients with positive peritoneal lavage cytology (CY1) and/or localized Peritoneum Metastasis (P1a) are defined as stage IV in the 15th edition of the Japanese Classification of Gastric Cancer. In Japan, the most common treatment for patients with CY1 and/or P1a is gastrectomy followed by postoperative chemotherapy. Subjects in this multi-institutional retrospective study were GC patients with CY1 and/or P1a who received surgical resection that leaves no macroscopically visible disease. Patients were selected from 34 institutions in Japan between 2007 and 2012. Selection criteria included adenocarcinoma, no distant Metastasis except CY1 and P1a, and no prior treatment for GC before surgery. Among 824 patients registered, 506 were identified as eligible, with a background of P0CY1, P1aCY0, or P1aCY1 (72.5%, 16.0%, and 11.5% of subjects, respectively). Sixty-two patients had not received postoperative chemotherapy (no-Cx), whereas 444 patients had received postoperative chemotherapy: S-1 monotherapy (S-1; n = 267, 52.7%), cisplatin plus S-1 (CS; n = 114, 22.5%), and others (n = 63, 12.6%). Overall survival (OS) was 29.5, 24.7, 25.4 and 9.9 months in the S-1, CS, ‘others’, and no-Cx groups, respectively [CS vs. S-1: hazard ratio (HR) 1.15, 95% confidence interval (CI) 0.89–1.50; p = 0.275]. In multivariate analysis, OS was similar between the S-1 and CS groups (CS vs. S-1: HR 1.19, 95% CI 0.92–1.55; p = 0.18). Postoperative chemotherapy after gastrectomy that leaves no macroscopically visible disease may have some survival benefits for GC patients with CY1 and/or P1a. In contrast, S-1 plus cisplatin seems to have no additional benefit over S-1 treatment alone.

  • the impact of pre operative chemotherapy in patients with peritoneal lavage cytology positive or localized Peritoneum Metastasis for gastric cancer a multicenter retrospective study
    Journal of Clinical Oncology, 2018
    Co-Authors: Rie Makuuchi, Toshifumi Yamaguchi, Atsuo Takashima, Kengo Nagashima, Tatsuya Yamada, Takahiro Kinoshita, Hiroaki Hata, Yasuyuki Kawachi, Ryohei Kawabata, Toshikatsu Tsuji
    Abstract:

    95Background: Peritoneal lavage cytology of positive and localized Peritoneum Metastasis of gastric cancer (GC) are defined as CY1 and P1 in the 14th edition of the Japanese Classification of GC. P...

  • comparison of s 1 and s 1 plus cisplatin as post operative chemotherapy for gastric carcinoma with peritoneal lavage cytology positive or localized Peritoneum Metastasis a multicenter retrospective study
    Journal of Clinical Oncology, 2018
    Co-Authors: Masaki Aizawa, Toshifumi Yamaguchi, Atsuo Takashima, Kengo Nagashima, Akira Ema, Yasuhiro Yuasa, Shusuke Haruta, Hiroki Taniguchi, Daisuke Kobayashi, Kazuhiro Nishikawa
    Abstract:

    109Background: Peritoneal lavage cytology of class V and localized Peritoneum Metastasis of gastric cancer (GC) are defined as CY1 and P1 in the 14th edition of the Japanese Classification of GC. Because patients (pts) with CY1 and/or P1 have poor prognosis after resecting all macroscopically visible disease by standard surgical resection, post-operative chemotherapy (post-Cx) is commonly performed in the clinical practice in Japan. However, no standard chemotherapy has not been established. The aim of this study was to investigate the efficacy of post-Cx in patients with CY1 and/or P1. Methods: We retrospectively reviewed the GC pts who were diagnosed to have CY1 and/or P1 at 34 institutions participating in the Stomach Cancer Group of Japan Clinical Oncology Group between 2007 and 2012. Inclusion criteria were: PS 0-2, histology of adenocarcinoma, no distant Metastasis other than CY1 or P1, no prior treatment for GC. The subject of this study was the patients who received surgery followed by post-Cx. Re...

Kengo Nagashima - One of the best experts on this subject based on the ideXlab platform.

  • efficacy of postoperative chemotherapy after resection that leaves no macroscopically visible disease of gastric cancer with positive peritoneal lavage cytology cy1 or localized Peritoneum Metastasis p1a a multicenter retrospective study
    Annals of Surgical Oncology, 2020
    Co-Authors: Toshifumi Yamaguchi, Rie Makuuchi, Atsuo Takashima, Kengo Nagashima, Tatsuya Yamada, Takahiro Kinoshita, Masaki Aizawa, Manabu Ohashi, Keitaro Tashiro, Hiroaki Hata
    Abstract:

    Gastric cancer (GC) patients with positive peritoneal lavage cytology (CY1) and/or localized Peritoneum Metastasis (P1a) are defined as stage IV in the 15th edition of the Japanese Classification of Gastric Cancer. In Japan, the most common treatment for patients with CY1 and/or P1a is gastrectomy followed by postoperative chemotherapy. Subjects in this multi-institutional retrospective study were GC patients with CY1 and/or P1a who received surgical resection that leaves no macroscopically visible disease. Patients were selected from 34 institutions in Japan between 2007 and 2012. Selection criteria included adenocarcinoma, no distant Metastasis except CY1 and P1a, and no prior treatment for GC before surgery. Among 824 patients registered, 506 were identified as eligible, with a background of P0CY1, P1aCY0, or P1aCY1 (72.5%, 16.0%, and 11.5% of subjects, respectively). Sixty-two patients had not received postoperative chemotherapy (no-Cx), whereas 444 patients had received postoperative chemotherapy: S-1 monotherapy (S-1; n = 267, 52.7%), cisplatin plus S-1 (CS; n = 114, 22.5%), and others (n = 63, 12.6%). Overall survival (OS) was 29.5, 24.7, 25.4 and 9.9 months in the S-1, CS, ‘others’, and no-Cx groups, respectively [CS vs. S-1: hazard ratio (HR) 1.15, 95% confidence interval (CI) 0.89–1.50; p = 0.275]. In multivariate analysis, OS was similar between the S-1 and CS groups (CS vs. S-1: HR 1.19, 95% CI 0.92–1.55; p = 0.18). Postoperative chemotherapy after gastrectomy that leaves no macroscopically visible disease may have some survival benefits for GC patients with CY1 and/or P1a. In contrast, S-1 plus cisplatin seems to have no additional benefit over S-1 treatment alone.

  • the impact of pre operative chemotherapy in patients with peritoneal lavage cytology positive or localized Peritoneum Metastasis for gastric cancer a multicenter retrospective study
    Journal of Clinical Oncology, 2018
    Co-Authors: Rie Makuuchi, Toshifumi Yamaguchi, Atsuo Takashima, Kengo Nagashima, Tatsuya Yamada, Takahiro Kinoshita, Hiroaki Hata, Yasuyuki Kawachi, Ryohei Kawabata, Toshikatsu Tsuji
    Abstract:

    95Background: Peritoneal lavage cytology of positive and localized Peritoneum Metastasis of gastric cancer (GC) are defined as CY1 and P1 in the 14th edition of the Japanese Classification of GC. P...

  • comparison of s 1 and s 1 plus cisplatin as post operative chemotherapy for gastric carcinoma with peritoneal lavage cytology positive or localized Peritoneum Metastasis a multicenter retrospective study
    Journal of Clinical Oncology, 2018
    Co-Authors: Masaki Aizawa, Toshifumi Yamaguchi, Atsuo Takashima, Kengo Nagashima, Akira Ema, Yasuhiro Yuasa, Shusuke Haruta, Hiroki Taniguchi, Daisuke Kobayashi, Kazuhiro Nishikawa
    Abstract:

    109Background: Peritoneal lavage cytology of class V and localized Peritoneum Metastasis of gastric cancer (GC) are defined as CY1 and P1 in the 14th edition of the Japanese Classification of GC. Because patients (pts) with CY1 and/or P1 have poor prognosis after resecting all macroscopically visible disease by standard surgical resection, post-operative chemotherapy (post-Cx) is commonly performed in the clinical practice in Japan. However, no standard chemotherapy has not been established. The aim of this study was to investigate the efficacy of post-Cx in patients with CY1 and/or P1. Methods: We retrospectively reviewed the GC pts who were diagnosed to have CY1 and/or P1 at 34 institutions participating in the Stomach Cancer Group of Japan Clinical Oncology Group between 2007 and 2012. Inclusion criteria were: PS 0-2, histology of adenocarcinoma, no distant Metastasis other than CY1 or P1, no prior treatment for GC. The subject of this study was the patients who received surgery followed by post-Cx. Re...

Rie Makuuchi - One of the best experts on this subject based on the ideXlab platform.

  • efficacy of postoperative chemotherapy after resection that leaves no macroscopically visible disease of gastric cancer with positive peritoneal lavage cytology cy1 or localized Peritoneum Metastasis p1a a multicenter retrospective study
    Annals of Surgical Oncology, 2020
    Co-Authors: Toshifumi Yamaguchi, Rie Makuuchi, Atsuo Takashima, Kengo Nagashima, Tatsuya Yamada, Takahiro Kinoshita, Masaki Aizawa, Manabu Ohashi, Keitaro Tashiro, Hiroaki Hata
    Abstract:

    Gastric cancer (GC) patients with positive peritoneal lavage cytology (CY1) and/or localized Peritoneum Metastasis (P1a) are defined as stage IV in the 15th edition of the Japanese Classification of Gastric Cancer. In Japan, the most common treatment for patients with CY1 and/or P1a is gastrectomy followed by postoperative chemotherapy. Subjects in this multi-institutional retrospective study were GC patients with CY1 and/or P1a who received surgical resection that leaves no macroscopically visible disease. Patients were selected from 34 institutions in Japan between 2007 and 2012. Selection criteria included adenocarcinoma, no distant Metastasis except CY1 and P1a, and no prior treatment for GC before surgery. Among 824 patients registered, 506 were identified as eligible, with a background of P0CY1, P1aCY0, or P1aCY1 (72.5%, 16.0%, and 11.5% of subjects, respectively). Sixty-two patients had not received postoperative chemotherapy (no-Cx), whereas 444 patients had received postoperative chemotherapy: S-1 monotherapy (S-1; n = 267, 52.7%), cisplatin plus S-1 (CS; n = 114, 22.5%), and others (n = 63, 12.6%). Overall survival (OS) was 29.5, 24.7, 25.4 and 9.9 months in the S-1, CS, ‘others’, and no-Cx groups, respectively [CS vs. S-1: hazard ratio (HR) 1.15, 95% confidence interval (CI) 0.89–1.50; p = 0.275]. In multivariate analysis, OS was similar between the S-1 and CS groups (CS vs. S-1: HR 1.19, 95% CI 0.92–1.55; p = 0.18). Postoperative chemotherapy after gastrectomy that leaves no macroscopically visible disease may have some survival benefits for GC patients with CY1 and/or P1a. In contrast, S-1 plus cisplatin seems to have no additional benefit over S-1 treatment alone.

  • the impact of pre operative chemotherapy in patients with peritoneal lavage cytology positive or localized Peritoneum Metastasis for gastric cancer a multicenter retrospective study
    Journal of Clinical Oncology, 2018
    Co-Authors: Rie Makuuchi, Toshifumi Yamaguchi, Atsuo Takashima, Kengo Nagashima, Tatsuya Yamada, Takahiro Kinoshita, Hiroaki Hata, Yasuyuki Kawachi, Ryohei Kawabata, Toshikatsu Tsuji
    Abstract:

    95Background: Peritoneal lavage cytology of positive and localized Peritoneum Metastasis of gastric cancer (GC) are defined as CY1 and P1 in the 14th edition of the Japanese Classification of GC. P...

Toshikatsu Tsuji - One of the best experts on this subject based on the ideXlab platform.